<DOC>
	<DOCNO>NCT01179776</DOCNO>
	<brief_summary>Acute myocardial infarct patient STEMI ( ST-elevation ECG ) undergo primary percutaneous cardiac intervention follow standard treatment , receive low dose Ilomedin low dose standard treatment another 24 hour .</brief_summary>
	<brief_title>Ilomedin Treatment Patients Having Undergone Primary Percutaneous Coronary Intervention ( PCI )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . Undergoing primary PCI due STEMI ( TIMI flow I III PCI symptom duration &lt; 12 hour ) 6 ) Following receipt verbal write information study , patient must provide sign informed consent study data use . 2 ) Not able give inform consent 3 ) Women childbearing potential 4 ) Ongoing concomitant treatment Kvitamin antagonists ( one bolus dose prePCI allow ) 5 ) Known congenital acquire coagulopathy and/or thrombocytopathy 8 ) Participation clinical study and/or another investigational device within past four week prior Day 1 9 ) Major surgery trauma within past 6 week prior Day 1 10 ) A blood coagulation disorder ( i.e . international normalized ratio [ INR ] &gt; 2.0 , platelet count &lt; 100,000/mm3 , hematocrit &lt; 30 % ) 11 ) Renal insufficiency ( creatinine &gt; 140 mmol/l ) 12 ) Major procedure relate bleeding ( TIMI major criterion ) ; GI urinary tract bleed prior inclusion trial 13 ) Known active hepatitis B and/or hepatitis C HIV 14 ) Known suspected hypersensitivity component investigational medicinal product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>ST-eleveation</keyword>
	<keyword>Myocardial infarct</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Myocardial infarct STEMI patient</keyword>
</DOC>